ES2647917T3 - Neuregulina para uso en el tratamiento de una lesión de nervio periférico - Google Patents

Neuregulina para uso en el tratamiento de una lesión de nervio periférico Download PDF

Info

Publication number
ES2647917T3
ES2647917T3 ES13716919.9T ES13716919T ES2647917T3 ES 2647917 T3 ES2647917 T3 ES 2647917T3 ES 13716919 T ES13716919 T ES 13716919T ES 2647917 T3 ES2647917 T3 ES 2647917T3
Authority
ES
Spain
Prior art keywords
injury
weeks
nerve
animals
ggf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13716919.9T
Other languages
English (en)
Spanish (es)
Inventor
Anthony O. Caggiano
Anthony J. Bella
Anindita Ganguly
Jennifer Iaci
Thomas Parry
Raymond Warren COLBURN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of ES2647917T3 publication Critical patent/ES2647917T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES13716919.9T 2012-03-30 2013-03-29 Neuregulina para uso en el tratamiento de una lesión de nervio periférico Active ES2647917T3 (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261618381P 2012-03-30 2012-03-30
US201261618381P 2012-03-30
US201261674060P 2012-07-20 2012-07-20
US201261674060P 2012-07-20
US201261693589P 2012-08-27 2012-08-27
US201261693585P 2012-08-27 2012-08-27
US201261693589P 2012-08-27
US201261693585P 2012-08-27
US201361785419P 2013-03-14 2013-03-14
US201361785419P 2013-03-14
PCT/US2013/034634 WO2013149163A1 (en) 2012-03-30 2013-03-29 Use of neuregulin to treat peripheral nerve injury

Publications (1)

Publication Number Publication Date
ES2647917T3 true ES2647917T3 (es) 2017-12-27

Family

ID=48128617

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13716919.9T Active ES2647917T3 (es) 2012-03-30 2013-03-29 Neuregulina para uso en el tratamiento de una lesión de nervio periférico
ES17187879T Active ES2857810T3 (es) 2012-03-30 2013-03-29 Uso de GGF2 para tratar el dolor neuropático luego de lesión del nervio periférico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17187879T Active ES2857810T3 (es) 2012-03-30 2013-03-29 Uso de GGF2 para tratar el dolor neuropático luego de lesión del nervio periférico

Country Status (15)

Country Link
US (3) US20150094263A1 (https=)
EP (3) EP3842059A1 (https=)
JP (4) JP6420233B2 (https=)
CN (2) CN104321072A (https=)
AU (4) AU2013237896B2 (https=)
BR (1) BR112014024308B1 (https=)
CA (1) CA2869070A1 (https=)
DK (2) DK3278811T3 (https=)
ES (2) ES2647917T3 (https=)
IL (3) IL288785B2 (https=)
MX (1) MX354598B (https=)
NZ (1) NZ700546A (https=)
PL (2) PL2830645T3 (https=)
PT (2) PT2830645T (https=)
WO (1) WO2013149163A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
NZ625673A (en) 2009-10-14 2015-11-27 Acorda Therapeutics Inc Use of a neuregulin to treat peripheral nerve injury
ITUB20155471A1 (it) * 2015-11-11 2017-05-11 Univ Degli Studi Di Torino Coniugato della neuregulina 1 per il trattamento delle lesioni dei nervi periferici
WO2017096358A1 (en) * 2015-12-04 2017-06-08 University Of Iowa Research Foundation Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
CN110946991A (zh) * 2018-09-27 2020-04-03 广州中医药大学(广州中医药研究院) 神经调节蛋白1的应用
WO2021022254A2 (en) * 2019-08-01 2021-02-04 Mark Evans Methods and apparatus for reducing the risk, and identifying the existence, of neurological injury to a human fetus during and before labor
CN116116737B (zh) * 2023-04-14 2023-06-30 新华手术器械有限公司 止血钳毛坯自动上料装置及使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037A (en) 1850-01-22 Grid-ikon slide-valve
US888A (en) 1838-08-20 perkins
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
AU745324B2 (en) * 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
AU2001274947B2 (en) * 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20100286043A1 (en) * 2007-10-05 2010-11-11 Tufts Medical Center, Inc. Use of neuregulin-1 in reducing brain damage
WO2009108390A2 (en) * 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
KR101237927B1 (ko) * 2009-05-07 2013-03-04 (주)문엔제이 신경손상 및 신경질환 예방 또는 치료용 약학조성물
NZ625673A (en) * 2009-10-14 2015-11-27 Acorda Therapeutics Inc Use of a neuregulin to treat peripheral nerve injury
EP2603221A4 (en) * 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION

Also Published As

Publication number Publication date
NZ700546A (en) 2017-05-26
IL273186A (en) 2020-04-30
IL234882B (en) 2020-03-31
PT3278811T (pt) 2021-03-03
US20150094263A1 (en) 2015-04-02
IL288785B (en) 2022-11-01
AU2013237896A1 (en) 2014-10-16
IL288785A (en) 2022-02-01
JP2021059605A (ja) 2021-04-15
ES2857810T3 (es) 2021-09-29
AU2013237896B2 (en) 2017-11-02
PL3278811T3 (pl) 2021-08-02
JP7108724B2 (ja) 2022-07-28
CA2869070A1 (en) 2013-10-03
JP2019131582A (ja) 2019-08-08
JP6420233B2 (ja) 2018-11-07
EP3278811A1 (en) 2018-02-07
MX354598B (es) 2018-03-12
BR112014024308B1 (pt) 2021-11-30
EP2830645B1 (en) 2017-08-30
DK2830645T3 (da) 2017-11-20
HK1249038A1 (en) 2018-10-26
DK3278811T3 (da) 2021-03-01
AU2019202401B2 (en) 2020-10-15
JP2017149746A (ja) 2017-08-31
AU2020260539A1 (en) 2020-11-26
PT2830645T (pt) 2017-11-28
JP2015514096A (ja) 2015-05-18
EP3842059A1 (en) 2021-06-30
MX2014011838A (es) 2015-03-09
HK1206632A1 (en) 2016-01-15
BR112014024308A8 (pt) 2018-01-23
US20160346353A1 (en) 2016-12-01
PL2830645T3 (pl) 2018-01-31
WO2013149163A1 (en) 2013-10-03
EP3278811B1 (en) 2020-12-02
IL288785B2 (en) 2023-03-01
AU2019202401A1 (en) 2019-05-02
BR112014024308A2 (pt) 2017-08-08
EP2830645A1 (en) 2015-02-04
AU2018200592A1 (en) 2018-02-15
IL234882A0 (en) 2014-12-31
US20230117985A1 (en) 2023-04-20
CN104321072A (zh) 2015-01-28
CN106511971A (zh) 2017-03-22
IL273186B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
ES2647917T3 (es) Neuregulina para uso en el tratamiento de una lesión de nervio periférico
US20220306704A1 (en) Neurotoxins for use in inhibiting cgrp
Srinivas et al. Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature
ES2374712T3 (es) Proteína antisecretora para uso en el tratamiento del síndrome compartimental.
ES2439740T3 (es) Tratamientos para trastornos neurológicos
KR20050109969A (ko) 보툴리눔 톡신으로 부비동염 관련 만성 안면통 및 두통을치료하는 방법
Yin et al. Transcorneal electrical stimulation promotes survival of retinal ganglion cells after optic nerve transection in rats accompanied by reduced microglial activation and TNF-α expression
Hajimashhadi et al. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats
ES2880807T3 (es) Administración intranasal de agentes con actividad pro-inflamatoria para la terapia de trastornos neurológicos
Welin et al. Effects of N-acetyl-cysteine on the survival and regeneration of sural sensory neurons in adult rats
Smith et al. Effects of nicotinamide on spatial memory and inflammation after juvenile traumatic brain injury
US20250134946A1 (en) Self-assembling amphiphilic peptide hydrogels for treatment of nerve injury
Uzun et al. Evaluation and comparison of the effects of artesunate, dexamethasone, and tacrolimus on sciatic nerve regeneration
Johnson et al. Combined regenerative rehabilitation improves recovery following volumetric muscle loss injury in a rat model
ES2763086T3 (es) Uso de una neuregulina para tratar la lesión del nervio periférico
ES2930077T3 (es) Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria
Feng et al. Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016)
KR20190142404A (ko) 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
ES2771448T3 (es) La protamina en el tratamiento de las lesiones neuronales
Sohn et al. Microelectric Treatment by Transcutaneous Electrical Nerve Stimulation in a Rat Model of Acute Spinal Cord Injury
Ara et al. Effect of various treatment modalities after spinal cord injury
Archer et al. The skin and the nervous system
US20120225821A1 (en) Composition for preventing or treating a spinal cord injury
Mansouri et al. The effects of dexamethasone and erythropoietin on mice sciatic nerve crush injury: histopathologic and functional outcomes.
RU2201266C2 (ru) Способ лечения болевых и компрессионных синдромов поясничного остеохондроза